T

he age of RNA interference drugs has arrived.

Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.)

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Seems a very small market(10,000) as I read it. Won’t the cost to consumer be astronomical! Happy for victims of FAP however.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X